Aktis Oncology, Inc.
NASDAQ:AKTSBiotechnology
+$0.11 today
- Market cap
- $865.32M
- Beta
- 1.10
- P/E (TTM)
- -28.7
- EPS (TTM)
- -$0.82
Volume 0.44M
Average 0.33M
AKTS Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Aktis Oncology, Inc.NASDAQ: AKTS
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) of $28.11M in Q1 FY2026
Q1 FY2026 property, plant & equipment (net) was $28.11M. Over 3 fiscal years it compounded at +77.6% a year.
Context
- Property, plant & equipment (net) amounted to 4.9% of total assets at the end of Q1 FY2026.
- Property, plant & equipment (net) increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 27.25M USD
- Year-over-year change
- +30.5%
- 3-year CAGR
- +77.6%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 27.25M | +30.5% |
| FY2024 | 2024-12-31 | 20.87M | -0.3% |
| FY2023 | 2023-12-31 | 20.92M | +330.1% |
| FY2022 | 2022-12-31 | 4.87M | — |
Property, Plant & Equipment (Net) vs competitors
How AKTS compares with its peers on the latest reported figures
- AKTS's Mar 2026 property, plant & equipment (net) of $28.11M is the 3rd highest of the 6 companies compared; the peer median is $20.55M.
- Property, plant & equipment (net) amounts to 4.9% of total assets for AKTS, versus a peer median of 4.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $49.67M | +3.7% | +9.0% | 4.6% | |
| Mar 2026 | $33.97M | -17.1% | -14.5% | 15.6% | |
| Mar 2026 | $28.11M | — | +77.6% | 4.9% | |
| Sep 2026 | $20.55M | +39.9% | +163.3% | 4.1% | |
| Mar 2026 | $20.27M | +31.2% | -12.6% | 3.1% | |
| Mar 2026 | $17.89M | -11.1% | -10.8% | 13.0% | |
| Peer median (excluding AKTS) | $20.55M | +3.7% | -10.8% | 4.6% | |
Competitors are the stored peer set for AKTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aktis Oncology, Inc.
NASDAQ:AKTS
Intrinsic Alpha fair value
Locked
Current Price
$16.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.